| Literature DB >> 28879161 |
Heidi Albert1, Jean de Dieu Iragena2, Kekeletso Kao3, Donatelle Erni3, Teferi Mekonen4, Philip C Onyebujoh5.
Abstract
BACKGROUND: Laboratory services are essential at all stages of the tuberculosis care cascade, from diagnosis and drug resistance testing to monitoring response to treatment. Enabling access to quality services is a challenge in low-resource settings. Implementation of a strong quality management system (QMS) and laboratory accreditation are key to improving patient care.Entities:
Year: 2017 PMID: 28879161 PMCID: PMC5523922 DOI: 10.4102/ajlm.v6i2.490
Source DB: PubMed Journal: Afr J Lab Med ISSN: 2225-2002
National Tuberculosis Reference Laboratory Accreditation Preparedness Survey questions
| Questions | Possible responses | |
|---|---|---|
| 1 | National Tuberculosis Reference Laboratory contact information | Name, institution, address, city, postal code and country |
| 2 | Head of National Tuberculosis Reference Laboratory contact information | Name, job title, email and phone number |
| 3 | Which of the tools for implementing QMS are you aware of? | Global Laboratory Initiative (GLI) Stepwise Process Towards TB Laboratory Accreditation |
| 4 | Is your laboratory actively implementing a QMS towards accreditation using the GLI tool ( | Yes / No / Partially |
| 5 | If the answer to Q4 is yes, please indicate the phase of implementation (i.e. Phase 1, Phase 2, Phase 3 or Phase 4) | Phase 1 |
| 6 | Has the National TB Reference Laboratory received an audit using the SLIPTA checklist? | Yes / No / Audit planned but not yet conducted |
| 7 | If the answer to Q6 is yes, what was the date of last audit? | |
| 8 | If the answer to Q6 is yes, what score and star grading did your laboratory achieve? | 0 stars (0–141 points) |
| 9 | Has your country appointed a SLIPTA focal person? | Yes / No |
| 10 | Have you included a budget and workplan for accreditation in your National Strategic Plan or Global Fund concept note? | Yes / No |
| 11 | If the answer to Q10 is yes, do you receive technical or financial support for accreditation? | Financial |
| 12 | If the answer to Q10 is affirmative, please name organisation providing support | Name |
| 13 | If not working towards accreditation currently, what are the main reasons? | Lack of knowledge of staff |
| 14 | Are staff from your TB laboratory participating in SLMTA or TB-SLMTA programme? | SLMTA |
| 15 | Do you have a Formal Collaboration Agreement with a WHO Tuberculosis Supranational Reference Laboratory (SRL)? | Yes / No |
| 16 | If the answer to Q15 is yes, what is the name of the SRL | SRL Name |
| 17 | If the answer to Q15 is no, which SRL would you like to be linked to and have a formal agreement signed? | SRL Name |
| 18 | If the answer to Q15 is yes, what is the nature of support you receive? | Financial |
| 19 | Please list the type of support related to quality assurance or quality management system you received from each WHO SRL | |
| 20 | Does your laboratory participate in the following External Quality Assurance (EQA) programmes coordinated by WHO SRL(s)? | AFB smear microscopy |
| 21 | Does your laboratory participate in the following External Quality Assurance (EQA) programmes coordinated by other providers? | AFB smear microscopy |
| 22 | If your laboratory participates in EQA programme, please provide name (s) of EQA provider | EQA Provider name |
| 23 | Please provide any additional information related to your laboratory’s progress towards accreditation | |
| 24 | What is, in your view, the major barrier for implementing the Quality Management System in your laboratories using the available tools? | |
| 25 | Please provide SLIPTA focal person contact details in case your country has appointed that person | Full name |
AFB, acid-fast bacilli; GLI, Global Laboratory Initiative; EQA, external quality assurance; LQMS, Laboratory Quality Management System; QMS, Quality Management System; SLIPTA, Stepwise Laboratory Quality Improvement Process Towards Accreditation; SLMTA, Strengthening Laboratory Management Toward Accreditation; SRL, Supranational Reference Laboratory TB, tuberculosis; WHO, World Health Organization.
FIGURE 1Implementation of GLI and SLMTA/TB-SLMTA approaches by National Tuberculosis Reference Laboratories in the World Health Organization’s African Region†
FIGURE 2National Tuberculosis Reference Laboratories in the World Health Organization’s Africa Region† whose staff participated in SLMTA/TB-SLMTA training, according to country survey response language.
FIGURE 3Auditing of National Tuberculosis Reference Laboratories in the World Health Organization’s African Region† using the Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA) checklist, date of last audit and SLIPTA star grading achieved at last audit.
FIGURE 4Collaboration agreements established between World Health Organization Supranational Reference Laboratories and National Tuberculosis Reference Laboratories (in the World Health Organization African Region†)
FIGURE 5Reasons reported by National Tuberculosis Reference Laboratories in the World Health Organization African Region† for not currently working towards accreditation.